HUS1: A Protein with Potential as A Drug Target Or Biomarker (G3364)

Target Name: HUS1

NCBI ID: G3364

HUS1

HUS1: A Protein with Potential as A Drug Target Or Biomarker

HUS1 (Hus1+-like protein) is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the HUS family of proteins, which are known for their role in the regulation of cell growth and differentiation. HUS1 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, HUS1 has potential as a drug target or biomarker.

The HUS family of proteins was identified through the analysis of genomic sequences. HUS1 and its related proteins share a conserved catalytic domain and a unique N-terminus that is involved in protein-protein interactions. HUS1 is a 14 kDa protein that has been shown to localize to the endoplasmic reticulum (ER) and to play a role in the regulation of protein stability and degradation.

HUS1 has been shown to be involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. It has been shown to promote the growth and survival of cancer cells, and to contribute to the development of neurodegenerative diseases. HUS1 has also been shown to play a role in the regulation of inflammation and immune responses.

In addition to its potential as a drug target or biomarker, HUS1 is also of interest as a potential therapeutic agent for a variety of diseases. For example, HUS1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. By targeting HUS1 with small molecules or other therapeutic agents, it may be possible to treat these diseases and improve the quality of life for those affected.

HUS1 is also of interest as a potential biomarker for certain diseases. For example, HUS1 has been shown to be involved in the regulation of inflammation and immune responses, and has been used as a potential biomarker for a variety of autoimmune disorders. By measuring the expression and activity of HUS1 in immune cells or tissues, it may be possible to diagnose and monitor the progression of these diseases.

In conclusion, HUS1 is a protein that has significant potential as a drug target or biomarker. Its role in the regulation of cellular processes and its involvement in the development and progression of various diseases make it an attractive target for therapeutic intervention. Further research is needed to fully understand the function and potential of HUS1, and to develop safe and effective drugs or other therapeutic agents that can target it.

Protein Name: HUS1 Checkpoint Clamp Component

Functions: Component of the 9-1-1 cell-cycle checkpoint response complex that plays a major role in DNA repair. The 9-1-1 complex is recruited to DNA lesion upon damage by the RAD17-replication factor C (RFC) clamp loader complex. Acts then as a sliding clamp platform on DNA for several proteins involved in long-patch base excision repair (LP-BER). The 9-1-1 complex stimulates DNA polymerase beta (POLB) activity by increasing its affinity for the 3'-OH end of the primer-template and stabilizes POLB to those sites where LP-BER proceeds; endonuclease FEN1 cleavage activity on substrates with double, nick, or gap flaps of distinct sequences and lengths; and DNA ligase I (LIG1) on long-patch base excision repair substrates. The 9-1-1 complex is necessary for the recruitment of RHNO1 to sites of double-stranded breaks (DSB) occurring during the S phase

The "HUS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HUS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets